EP 3837353 A1 20210623 - CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING KREBS CYCLE AND THERAPEUTIC USES THEREOF
Title (en)
CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING KREBS CYCLE AND THERAPEUTIC USES THEREOF
Title (de)
CHIMÄRE ANTIGENREZEPTOR-POLYPEPTIDE IN KOMBINATION MIT TRANSMETABOLISCHEN MOLEKÜLEN, DIE EINEN KREBS-ZYKLUS MODULIEREN, UND THERAPEUTISCHE VERWENDUNGEN DAVON
Title (fr)
RÉCEPTEURS D'ANTIGÈNE CHIMÉRIQUES EN ASSOCIATION AVEC DES MOLÉCULES DE TRANS-MÉTABOLISME MODULANT LE CYCLE DE KREBS ET LEURS UTILISATIONS THÉRAPEUTIQUES
Publication
Application
Priority
- US 201862718579 P 20180814
- US 201862718491 P 20180814
- US 2019046550 W 20190814
Abstract (en)
[origin: WO2020037066A1] Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.
IPC 8 full level
C12N 5/10 (2006.01); A61K 35/14 (2015.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP IL KR US)
A61K 35/17 (2013.01 - US); A61K 39/4611 (2023.05 - EP IL KR); A61K 39/4631 (2023.05 - EP IL KR); A61K 39/464474 (2023.05 - EP IL KR); A61K 48/005 (2013.01 - IL); A61P 35/00 (2018.01 - EP IL US); C07K 14/705 (2013.01 - EP IL); C07K 14/7051 (2013.01 - EP IL KR US); C07K 14/70514 (2013.01 - EP IL); C07K 14/70517 (2013.01 - EP IL US); C07K 14/70521 (2013.01 - KR US); C07K 14/70535 (2013.01 - EP IL KR); C07K 14/70578 (2013.01 - KR US); C07K 14/71 (2013.01 - EP IL); C07K 16/303 (2013.01 - US); C12N 5/0638 (2013.01 - EP IL KR); C12N 9/0006 (2013.01 - EP IL KR US); C12N 9/0016 (2013.01 - EP IL KR US); C12N 9/1096 (2013.01 - EP IL KR US); C12N 9/80 (2013.01 - EP IL KR US); C12N 9/88 (2013.01 - EP IL US); C12N 15/62 (2013.01 - KR); C12Y 101/01037 (2013.01 - EP IL KR US); C12Y 101/01041 (2013.01 - EP IL KR); C12Y 101/01042 (2013.01 - EP IL KR US); C12Y 101/01095 (2013.01 - EP IL KR); C12Y 104/01002 (2013.01 - EP IL US); C12Y 104/01003 (2013.01 - EP IL KR); C12Y 104/01004 (2013.01 - EP IL); C12Y 206/01001 (2013.01 - EP IL US); C12Y 206/01002 (2013.01 - EP IL US); C12Y 206/01015 (2013.01 - KR); C12Y 206/01052 (2013.01 - EP IL KR US); C12Y 305/01002 (2013.01 - EP IL KR US); C12Y 401/01032 (2013.01 - US); C12Y 401/01049 (2013.01 - EP IL); A61K 48/00 (2013.01 - US); A61K 48/005 (2013.01 - EP); A61K 2239/31 (2023.05 - EP IL KR); A61K 2239/38 (2023.05 - EP IL KR); A61K 2239/53 (2023.05 - EP IL KR); A61K 2239/55 (2023.05 - EP IL KR); C07K 2317/622 (2013.01 - KR); C07K 2319/02 (2013.01 - KR US); C07K 2319/03 (2013.01 - KR US); C07K 2319/30 (2013.01 - KR); C12N 2510/00 (2013.01 - EP IL KR); C12N 2740/14043 (2013.01 - EP IL KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020037066 A1 20200220; AU 2019321540 A1 20210211; BR 112021001694 A2 20210504; CA 3108126 A1 20200220; CN 112840019 A 20210525; EP 3837353 A1 20210623; EP 3837353 A4 20220518; IL 280322 A 20210325; JP 2021534740 A 20211216; JP 7456638 B2 20240327; KR 20210045418 A 20210426; MX 2021001771 A 20210716; SG 11202101284U A 20210330; US 2021332334 A1 20211028; ZA 202100993 B 20220928
DOCDB simple family (application)
US 2019046550 W 20190814; AU 2019321540 A 20190814; BR 112021001694 A 20190814; CA 3108126 A 20190814; CN 201980056166 A 20190814; EP 19849543 A 20190814; IL 28032221 A 20210121; JP 2021507503 A 20190814; KR 20217006593 A 20190814; MX 2021001771 A 20190814; SG 11202101284U A 20190814; US 201917268345 A 20190814; ZA 202100993 A 20210212